Brief Summary
“Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if different resistance mutations arise in these settings.”
“Patients with KRAS G12C mutant cancers will be enrolled in two cohorts.
Cohort 1A will enroll patients who are currently progressing on a KRAS G12C inhibitor and plasma for ctDNA analysis will be collected from these patients remotely.
Cohort 1B will enroll patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history with the study team. Plasma for ctDNA analysis will be optional for this cohort.
NCT05272423
Dr Mark Awad, M.D, Ph.D.on KRAS-Driven Cancers and Strategies to Overcome Resistance – November 2022 KRAS Kickers Video
Dr. Mark Awad “… providing the latest data on resistance in KRAS-driven cancers. Introducing the SPARK study protocol, he delved into crucial insights and answered attendees' questions, offering valuable perspectives on resistance, KRAS subtypes, and current trials and treatments available for patients.”
Mechanisms of KRAS Inhibitor Resistance Revealed (June 2021)
Comments